Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | IDE | P14735 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HLCS | P50747 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL13272362 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL10047687 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8763 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL38817 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL16897730 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL5690544 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120138181-A | Primer group for detecting mycoplasma pneumoniae and drug-resistant mutation thereof and application of primer group | 常州市儿童医院(常州市第六人民医院) | 2025-06-13 | — | — | CN | claimed |
| EP-4416303-A1 | A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL | Blink AG (DE) | 2024-08-21 | — | — | EP | claimed |
| CN-118510909-A | Microsphere comprising a first material and a second material | 布林克公司 | 2024-08-16 | — | — | CN | claimed |
| EP-4317163-A1 | METHOD FOR PREPARING BIOTIN, L-LYSINE SALT OF BIOTIN, AND METHOD FOR PREPARING SAME | Tokuyama Corporation (JP) | 2024-02-07 | — | — | EP | claimed |
| CN-117062820-A | Method for producing biotin, and L-lysine salt of biotin and method for producing same | 株式会社德山 | 2023-11-14 | — | — | CN | claimed |
| US-20230338553-A1 | DELIVERY SYSTEM FOR TARGETED DELIVERY OF A THERAPEUTICALLY ACTIVE PAYLOAD | Technische Universität Dresden (CH) | 2023-10-26 | — | — | US | claimed |
| WO-2023169899-A1 | TARGETED DELIVERY OF OLIGONUCLEOTIDES INTO EUKARYOTIC CELLS USING HYBRID MALTOSE/CYCLODEXTRIN POLYPLEXES | TECHNISCHE UNIVERSITÄT DRESDEN E.V. (DE) | 2023-09-14 | — | — | WO | claimed |
| EP-4238581-A1 | TARGETED DELIVERY OF OLIGONUCLEOTIDES INTO EUKARYOTIC CELLS USING HYBRID MALTOSE/CYCLODEXTRIN POLYPLEXES | Technische Universität Dresden e. V. (DE) | 2023-09-06 | — | — | EP | claimed |
| WO-2023079140-A1 | A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL | BLINK AG (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-4177352-A1 | A MICROSPHERE COMPRISING A FIRST MATERIAL AND A SECOND MATERIAL | Blink AG (DE) | 2023-05-10 | — | — | EP | claimed |
| US-20230126528-A1 | A LIBRARY OF PREFABRICATED MICROPARTICLES AND PRECURSORS THEREOF | BLINK AG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4078180-A1 | A LIBRARY OF PREFABRICATED MICROPARTICLES AND PRECURSORS THEREOF | Blink AG (DE) | 2022-10-26 | — | — | EP | claimed |
| CN-115176156-A | Library of preformed microparticles and precursors thereof | 布林克公司 | 2022-10-11 | — | — | CN | claimed |
| WO-2022202982-A1 | METHOD FOR PREPARING BIOTIN, L-LYSINE SALT OF BIOTIN, AND METHOD FOR PREPARING SAME | 株式会社トクヤマ | 2022-09-29 | — | — | WO | claimed |
| CN-114540465-A | RPA amplification method suitable for low abundance sample detection | 中国疾病预防控制中心传染病预防控制所 | 2022-05-27 | — | — | CN | claimed |
| EP-3729090-B1 | MODIFIED BIOTIN-BINDING PROTEINS FOR IMMOBILIZATION | PACIFIC BIOSCIENCES CALIFORNIA INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20070141105-A1 | Engineered Biological Matrices | CAMBREX BIO SCIENCE WALKERSVILLE, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070141105-A1 | Engineered Biological Matrices | CAMBREX BIO SCIENCE WALKERSVILLE, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2007044669-A2 | ENGINEERED BIOLOGICAL MATRICES | LONZA WALKERSVILLE, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141105-A1 | Engineered Biological Matrices | BMP2, HMGB1, BMP4 | TDP1 2232/4885MEN1 4142/4885ABL1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.